Approval · Notice of Compliance 36983 · 2026
OKEDI: Notice of Compliance 36983
Issued February 25, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36983
- Date
- February 25, 2026
- Company
- Laboratorios Farmaceuticos Rovi, S.A.Madrid, Madrid, Spain
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Replacement of a drug product manufacturing site and/or manufacturer involving production
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| OKEDI | Not yet assigned | — |
Medicinal ingredients
- RISPERIDONE 75 MG per UNIT
- RISPERIDONE 100 MG per UNIT